Global Health Limited Reports 33.6% Revenue Growth in Q2 FY27

Global Health Limited reported Q2 FY27 revenue of INR 14,690 million, up 33.6% year-on-year, with profit after tax rising 38.3% to INR 2,191 million as patient volumes increased across its hospital network. The performance matters because it combines volume growth, stable operating margins and a sizeable hospital expansion programme.

What did Global Health report for Q2 FY27?

Global Health reported consolidated revenue of INR 14,690 million for Q2 FY27, a 33.6% increase from the corresponding quarter of the previous year. Operating EBITDA was INR 3,701 million, translating into an operating EBITDA margin of 25.2%. Profit after tax stood at INR 2,191 million, up 38.3% year-on-year.

The company, which operates hospitals under the Medanta brand, presented the figures in an investor presentation filed with BSE and NSE on November 3, 2026. The presentation attributed growth to higher patient volumes and expanding capacity across its network. No explicit revenue or profit growth guidance was disclosed for the remainder of FY27.

The reported result follows a strong first quarter. In Q1 FY27, revenue was INR 13,262 million, up 26% year-on-year, while reported EBITDA was INR 3,153 million and the margin was 23.8%. The second-quarter numbers therefore show a higher revenue base and an improvement in the reported operating margin compared with Q1.

Which operating metrics supported Global Health's growth?

Patient volumes were the main driver of Global Health's Q2 FY27 performance, with inpatient department volumes rising 29.5% year-on-year and occupied bed days increasing 22.4%. Average revenue per patient, or ARPP, was INR 0.206 million, up 2.7% year-on-year.

The difference between volume growth and the modest ARPP increase indicates that the quarter's expansion was primarily volume-led rather than dependent on higher pricing. Census beds rose to 3,115 from 2,658, while occupancy was reported at 67%. The additional beds gave the company more capacity to treat patients while maintaining room for further utilisation growth.

Cluster 2 revenue increased 63.2% year-on-year, making it the fastest-growing reported business grouping in the presentation. The company did not provide a separate absolute revenue figure for Cluster 2 in the supplied disclosure, so its contribution to consolidated revenue cannot be quantified from the available information.

What expansion plans has Global Health disclosed?

Global Health has outlined plans to add about 3,450 beds over the next four to five years, backed by planned capital expenditure of INR 62,390 million. For the second half of FY27 alone, the company expects capital expenditure of INR 6,000 million.

The expansion plan is central to the company's stated growth strategy because hospital revenue depends on clinical capacity, patient demand and the pace at which new facilities mature. Higher bed capacity can support additional inpatient volumes, but new hospitals and beds also require capital, clinicians and operating infrastructure before they reach established utilisation levels.

The company had previously disclosed a pipeline of nearly 3,350 additional beds in its Q1 FY27 presentation. It also said its Guwahati hospital plan had been upscaled to 650 beds with capital expenditure of INR 9,700 million. The Q2 presentation's planned addition of about 3,450 beds indicates that the capacity programme remains a major operational focus.

How does the Q2 result compare with recent performance?

Global Health's Q2 FY27 revenue of INR 14,690 million was higher than the INR 13,262 million reported in Q1 FY27, while its operating EBITDA margin rose to 25.2% from 23.8%. Both quarters were supported by patient-volume growth and capacity additions, according to the investor presentations.

In Q1 FY27, inpatient volumes increased 28% year-on-year and reported EBITDA rose 23% year-on-year. The company also reported that its Noida facility was ahead of its internal financial return expectations. These disclosures provide context for the Q2 outcome, although the company has not published a specific consolidated growth target for FY27.

Global Health operates in India's private multi-specialty tertiary-care market, with a focus on North and East India. Its services include hospital care, diagnostics, pharmacy sales, homecare, telemedicine, air ambulance and e-ICU services. The breadth of services complements its hospital operations, although the provided presentation does not give separate financial performance for each service line.

What does the result mean for investors and operations?

For investors, the Q2 disclosure shows simultaneous growth in revenue, profit, patient volumes and bed capacity, alongside net cash of INR 7,815 million. The net cash position is relevant as Global Health pursues a multi-year capital expenditure plan of INR 62,390 million.

Operating margins also remain important because expansion can increase costs before new facilities achieve mature patient occupancy. The Q2 operating EBITDA margin of 25.2% was above the 23.8% reported in Q1 FY27, but the company has not provided a margin target for the full year or for its expansion projects.

The investor presentation did not state specific operating risks. Its standard disclaimer referred to macroeconomic conditions, competition, regulations and talent retention as factors that could affect forward-looking statements. These factors are relevant to hospital operators because healthcare delivery requires specialised medical professionals, regulatory compliance and sustained patient demand.

Conclusion

Global Health's Q2 FY27 results showed 33.6% year-on-year revenue growth to INR 14,690 million and a 38.3% increase in profit after tax to INR 2,191 million. Higher inpatient volumes, increased occupied bed days and a larger bed base supported the performance, while the 25.2% operating EBITDA margin indicated continued profitability during expansion.

The next key disclosures will be progress on the planned addition of about 3,450 beds, second-half FY27 capital expenditure of INR 6,000 million and the use of the company's INR 7,815 million net cash position. Investors will also watch occupancy, patient volumes and margins as the additional capacity is developed.